EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mayne Pharma Group's EBITDA for the
six
months ended in Dec. 2025 was A$41.9 Mil. Mayne Pharma Group's Revenue for the
six
months ended in Dec. 2025 was A$209.3 Mil. Therefore, Mayne Pharma Group's EBITDA margin for the quarter that ended in Dec. 2025 was 20.03%.
Mayne Pharma Group (ASX:MYX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Mayne Pharma Group EBITDA Margin % Related Terms
Mayne Pharma Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MYX vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mayne Pharma Group (ASX:MYX) has a EBITDA Margin % of 20.03% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #45 out of 119 companies in the Medical Distribution industry, placing it in the top 37.8%.
Is Mayne Pharma Group's EBITDA Margin % too high?
Mayne Pharma Group's current EBITDA Margin % is 20.03%. The Medical Distribution industry median EBITDA Margin % is 4.31. Mayne Pharma Group's value of 20.03% is 364.7% above this industry median. Based on the distribution chart, Mayne Pharma Group ranks #45 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Mayne Pharma Group has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #45 out of 119 companies for EBITDA Margin %. This puts Mayne Pharma Group in the upper half of its industry. The industry median EBITDA Margin % is 4.31. Mayne Pharma Group's value of 20.03% is 364.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mayne Pharma Group's current EBITDA Margin % of 20.03% is 364.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current EBITDA Margin % is 20.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (ASX:MYX) is currently considered Possible Value Trap. The stock's GF Value™ is A$5.31, compared to a current price of A$2.57 — trading 51.6% below its estimated fair value. The current EBITDA Margin % is 20.03% and 364.7% above the Medical Distribution industry median of 4.31. Mayne Pharma Group's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Mayne Pharma Group (ASX:MYX), the current EBITDA Margin % is 20.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (ASX:MYX) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of A$2.57 is trading 51.6% below its estimated GF Value™ of A$5.31.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for ASX:MYX:
EBITDA Margin %: 20.03%
GF Value™: A$5.31 vs. price of A$2.57 (51.6% below fair value)
Industry Position: 364.7% above the Medical Distribution median (#45 of 119)
No single metric tells the full story. See the ASX:MYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
51GF Score
Get the complete analysis for ASX:MYX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MYX has been successfully added to your 
